Delving into the Latest Updates on 台湾永生细胞股份有限公司 with Synapse

概览

关联

5

项与台湾永生细胞股份有限公司相关的临床试验

NCT06377982

/ Not yet recruiting临床1期

A Phase I, Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Safety and Efficacy of Allogeneic Human Umbilical Cord Blood Infusion in Children with Cerebral Palsy

A phase I, randomized, double-blind, placebo-controlled clinical study to assess the safety and efficacy of allogeneic human umbilical cord blood infusion in children with cerebral palsy

开始日期2025-09-01

申办/合作机构

台湾永生细胞股份有限公司

NCT06040476

/ Not yet recruiting临床2期

A Phase II, Randomized, Double-blind, Parallel, Placebo-controlled Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke

开始日期2025-09-01

申办/合作机构

StemCyte, Inc.

[+1]

NCT05682560

/ Active, not recruiting临床2期

A Randomized Controlled Phase IIa, Two-arm Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

RegeneCyte (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.

开始日期2023-05-04

申办/合作机构

StemCyte, Inc.

[+1]

100 项与台湾永生细胞股份有限公司相关的临床结果

登录后查看更多信息

0 项与台湾永生细胞股份有限公司相关的专利（医药）

登录后查看更多信息

100 项与台湾永生细胞股份有限公司相关的药物交易

登录后查看更多信息

100 项与台湾永生细胞股份有限公司相关的转化医学